SCHEMBL5540690

SCHEMBL5540690

CCOC(=O)CC(=O)N(CCCSC)c1cc(Cc2ccc(F)cc2)cnc1C(=O)OCC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.35
POLB P06746 1/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
MAPT P10636 3/20 0.34
LMNA P02545 2/20 0.34
KDM4E B2RXH2 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
ALOX12 P18054 1/20 0.34
CCR6 P51684 1/20 0.34
HKDC1 Q2TB90 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
LTA4H P09960 6/20 0.33
CXCR1 P25024 1/20 0.33
CXCR2 P25025 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
CASP3 P42574 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4585782 0.85 POLB (0.35) MAOBPOLBMEN1KMT2AMAPT
SCHEMBL5538668 0.84 PDE3B (0.40) POLBMAPTKDM4EALDH1A1TSHR
SCHEMBL5538835 0.84 PDE3B (0.38) MEN1KMT2AMAPTALDH1A1TSHR
SCHEMBL5547377 0.84 KDM4E (0.38) MAOBPOLBMEN1KMT2AMAPT
SCHEMBL5546803 0.83 MAPT (0.35) MAOBPOLBMEN1KMT2AMAPT
SCHEMBL5539039 0.83 ALDH1A1 (0.40) POLBMEN1KMT2AMAPTLMNA
SCHEMBL5543021 0.82 MAOB (0.41) MAOBPOLBMEN1KMT2AMAPT
SCHEMBL5544805 0.82 RAB9A (0.36) MAOBMEN1KMT2AMAPTLMNA
SCHEMBL5545354 0.82 EPHX2 (0.42) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL5545489 0.81 ALDH1A1 (0.41) POLBMEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed
EP-1720856-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP disclosed
WO-2005077050-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 MAOB 3126/4885POLB 113/4885MEN1 4802/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 MAOB 3594/4885POLB 115/4885MEN1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.